First Trust Advisors’s Nektar Therapeutics NKTR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | – | Sell |
-522,303
| Closed | -$29.8M | – | 2565 |
|
|
2022
Q2 | $29.8M | Buy |
522,303
+229,595
| +78% | +$14.5M | 0.04% | 576 |
|
|
2022
Q1 | $23.7M | Buy |
292,708
+64,726
| +28% | +$9.58M | 0.02% | 741 |
|
|
2021
Q4 | $46.2M | Sell |
227,982
-25,106
| -10% | -$5.45M | 0.04% | 524 |
|
|
2021
Q3 | $68.2M | Buy |
253,088
+36,061
| +17% | +$8.67M | 0.07% | 353 |
|
|
2021
Q2 | $55.9M | Sell |
217,027
-59,512
| -22% | -$16.5M | 0.06% | 446 |
|
|
2021
Q1 | $83M | Buy |
276,539
+22,258
| +9% | +$6.93M | 0.1% | 259 |
|
|
2020
Q4 | $64.8M | Buy |
254,281
+52,774
| +26% | +$13.6M | 0.09% | 313 |
|
|
2020
Q3 | $50.1M | Sell |
201,507
-25,096
| -11% | -$7.89M | 0.08% | 364 |
|
|
2020
Q2 | $78.7M | Buy |
226,603
+58,321
| +35% | +$18.2M | 0.14% | 181 |
|
|
2020
Q1 | $45.1M | Sell |
168,282
-29,681
| -15% | -$9.18M | 0.1% | 305 |
|
|
2019
Q4 | $64.1M | Buy |
197,963
+20,820
| +12% | +$6.04M | 0.11% | 260 |
|
|
2019
Q3 | $48.4M | Sell |
177,143
-23,257
| -12% | -$8.53M | 0.09% | 309 |
|
|
2019
Q2 | $107M | Buy |
200,400
+57,121
| +40% | +$28.6M | 0.2% | 114 |
|
|
2019
Q1 | $72.2M | Sell |
143,279
-10,666
| -7% | -$6.32M | 0.14% | 175 |
|
|
2018
Q4 | $75.9M | Buy |
153,945
+16,018
| +12% | +$9.67M | 0.18% | 126 |
|
|
2018
Q3 | $126M | Buy |
137,927
+87,985
| +176% | +$75.1M | 0.23% | 76 |
|
|
2018
Q2 | $36.6M | Buy |
49,942
+1,150
| +2% | +$1.33M | 0.08% | 308 |
|
|
2018
Q1 | $77.8M | Sell |
48,792
-64,917
| -57% | -$83.6M | 0.18% | 107 |
|
|
2017
Q4 | $102M | Buy |
113,709
+3,295
| +3% | +$1.95M | 0.24% | 76 |
|
|
2017
Q3 | $39.7M | Sell |
110,414
-5,127
| -4% | -$1.6M | 0.1% | 224 |
|
|
2017
Q2 | $33.9M | Sell |
115,541
-34,456
| -23% | -$9.96M | 0.09% | 264 |
|
|
2017
Q1 | $52.8M | Buy |
149,997
+11,102
| +8% | +$2.5M | 0.15% | 127 |
|
|
2016
Q4 | $25.6M | Buy |
138,895
+21,770
| +19% | +$4.43M | 0.08% | 347 |
|
|
2016
Q3 | $30.2M | Sell |
117,125
-12,937
| -10% | -$3.33M | 0.09% | 274 |
|
|
2016
Q2 | $27.8M | Sell |
130,062
-19,056
| -13% | -$4.26M | 0.09% | 285 |
|
|
2016
Q1 | $30.8M | Sell |
149,118
-490,823
| -77% | -$94.3M | 0.1% | 256 |
|
|
2015
Q4 | $162M | Sell |
639,941
-52,371
| -8% | -$10.8M | 0.42% | 27 |
|
|
2015
Q3 | $114M | Buy |
692,312
+43,889
| +7% | +$7.76M | 0.33% | 54 |
|
|
2015
Q2 | $122M | Buy |
648,423
+228,082
| +54% | +$39.3M | 0.32% | 57 |
|
|
2015
Q1 | $69.4M | Buy |
420,341
+86,093
| +26% | +$17.7M | 0.2% | 104 |
|
|
2014
Q4 | $77.7M | Sell |
334,248
-74,820
| -18% | -$16M | 0.26% | 71 |
|
|
2014
Q3 | $74.1M | Buy |
409,068
+58,617
| +17% | +$11.2M | 0.29% | 56 |
|
|
2014
Q2 | $67.4M | Buy |
350,451
+53,120
| +18% | +$9.39M | 0.28% | 48 |
|
|
2014
Q1 | $54.1M | Buy |
297,331
+9,651
| +3% | +$1.91M | 0.24% | 65 |
|
|
2013
Q4 | $49M | Buy |
287,680
+79,343
| +38% | +$12.8M | 0.24% | 64 |
|
|
2013
Q3 | $32.6M | Buy |
208,337
+59,624
| +40% | +$11M | 0.18% | 120 |
|
|
2013
Q2 | $25.8M | Buy |
+148,713
| New | +$22.8M | 0.17% | 140 |
|
Other funds holding NKTR
First Trust Advisors's NKTR Position: Q3 2022 in Review
First Trust Advisors sold out of Nektar Therapeutics (NKTR) in Q3 2022, closing a stake of 522,303 shares — an estimated $29.8M sold.
First Trust Advisors first reported a position in NKTR in Q2 2013 and held it in 37 quarters. The position peaked at $162M in Q4 2015. 230 funds tracked by Wall St. Rank hold NKTR as of Q3 2022.
- First Trust Advisors reported no remaining Nektar Therapeutics position as of Q3 2022 after selling out during the quarter.
- First Trust Advisors sold 522,303 Nektar Therapeutics shares in Q3 2022, an estimated $29.8M.
- First Trust Advisors first reported a position in Nektar Therapeutics in Q2 2013 and held it in 37 quarters.
- First Trust Advisors's Nektar Therapeutics position peaked at $162M in Q4 2015.
- 230 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2022.
Based on First Trust Advisors's 13F filing for Q3 2022, filed 14 Nov 2022.